Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
PRTA's Cash to Debt is ranked higher than
77% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 56.57 vs. PRTA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PRTA' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6648
N/A
No Debt
Equity to Asset 0.95
PRTA's Equity to Asset is ranked higher than
92% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PRTA: 0.95 )
Ranked among companies with meaningful Equity to Asset only.
PRTA' s Equity to Asset Range Over the Past 10 Years
Min: 0.91  Med: 0.95 Max: 0.98
Current: 0.95
0.91
0.98
F-Score: 2
Z-Score: 37.65
M-Score: 2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -7217.98
PRTA's Operating margin (%) is ranked lower than
91% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.21 vs. PRTA: -7217.98 )
Ranked among companies with meaningful Operating margin (%) only.
PRTA' s Operating margin (%) Range Over the Past 10 Years
Min: -5980.33  Med: -3266.12 Max: -13.07
Current: -7217.98
-5980.33
-13.07
Net-margin (%) -7265.91
PRTA's Net-margin (%) is ranked lower than
91% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. PRTA: -7265.91 )
Ranked among companies with meaningful Net-margin (%) only.
PRTA' s Net-margin (%) Range Over the Past 10 Years
Min: -6064.5  Med: -3287.14 Max: -14.06
Current: -7265.91
-6064.5
-14.06
ROE (%) -24.75
PRTA's ROE (%) is ranked higher than
56% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -31.69 vs. PRTA: -24.75 )
Ranked among companies with meaningful ROE (%) only.
PRTA' s ROE (%) Range Over the Past 10 Years
Min: -68.99  Med: -26.07 Max: -3.09
Current: -24.75
-68.99
-3.09
ROA (%) -23.51
PRTA's ROA (%) is ranked higher than
53% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -26.89 vs. PRTA: -23.51 )
Ranked among companies with meaningful ROA (%) only.
PRTA' s ROA (%) Range Over the Past 10 Years
Min: -1640.13  Med: -26.31 Max: -2.94
Current: -23.51
-1640.13
-2.94
ROC (Joel Greenblatt) (%) -2799.55
PRTA's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. PRTA: -2799.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRTA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2303.58  Med: -1384.72 Max: -204.81
Current: -2799.55
-2303.58
-204.81
Revenue Growth (3Y)(%) -33.70
PRTA's Revenue Growth (3Y)(%) is ranked lower than
79% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. PRTA: -33.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRTA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.7  Med: -25.20 Max: 289
Current: -33.7
-33.7
289
EBITDA Growth (3Y)(%) -2.40
PRTA's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. PRTA: -2.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRTA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.7  Med: -2.40 Max: 37.3
Current: -2.4
-50.7
37.3
EPS Growth (3Y)(%) -2.20
PRTA's EPS Growth (3Y)(%) is ranked higher than
54% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. PRTA: -2.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRTA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.9  Med: -2.20 Max: 36.8
Current: -2.2
-47.9
36.8
» PRTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

PRTA Guru Trades in Q2 2015

Steven Cohen 62,000 sh (New)
Paul Tudor Jones 12,142 sh (New)
Vanguard Health Care Fund 1,662,794 sh (unchged)
» More
Q3 2015

PRTA Guru Trades in Q3 2015

Jim Simons 36,400 sh (New)
Ken Fisher 19,040 sh (New)
Vanguard Health Care Fund 1,662,794 sh (unchged)
Paul Tudor Jones 5,601 sh (-53.87%)
Steven Cohen 16,900 sh (-72.74%)
» More
Q4 2015

PRTA Guru Trades in Q4 2015

Jim Simons 90,600 sh (+148.90%)
Ken Fisher 19,040 sh (unchged)
Vanguard Health Care Fund 1,662,794 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2016

PRTA Guru Trades in Q1 2016

Vanguard Health Care Fund 2,150,294 sh (+29.32%)
Ken Fisher 19,076 sh (+0.19%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:SHSE:600645, SHSE:600161, SHSE:603566, BOM:532523, NAS:NKTR, SZSE:300347 » details
Traded in other countries:0PT.Germany,
Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.

Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.

Top Ranked Articles about Prothena Corp PLC

The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Prothena Corp. tops the list with a 148% return year-to-date
Jean M. Hynes has managed the Vanguard Health Care Fund (Trades, Portfolio) (VGHCX) since 2008, which is now composed of 82 stocks. The following are the stocks in the portfolio with the highest performance since the beginning of the year. Read more...

Ratios

vs
industry
vs
history
P/B 3.43
PRTA's P/B is ranked higher than
51% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 3.51 vs. PRTA: 3.43 )
Ranked among companies with meaningful P/B only.
PRTA' s P/B Range Over the Past 10 Years
Min: 0.84  Med: 3.06 Max: 6.28
Current: 3.43
0.84
6.28
P/S 1135.61
PRTA's P/S is ranked lower than
96% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. PRTA: 1135.61 )
Ranked among companies with meaningful P/S only.
PRTA' s P/S Range Over the Past 10 Years
Min: 8.25  Med: 92.36 Max: 1291.45
Current: 1135.61
8.25
1291.45
Current Ratio 20.75
PRTA's Current Ratio is ranked higher than
92% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. PRTA: 20.75 )
Ranked among companies with meaningful Current Ratio only.
PRTA' s Current Ratio Range Over the Past 10 Years
Min: 12.51  Med: 23.91 Max: 72.16
Current: 20.75
12.51
72.16
Quick Ratio 20.75
PRTA's Quick Ratio is ranked higher than
92% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. PRTA: 20.75 )
Ranked among companies with meaningful Quick Ratio only.
PRTA' s Quick Ratio Range Over the Past 10 Years
Min: 12.51  Med: 23.91 Max: 72.16
Current: 20.75
12.51
72.16
Days Sales Outstanding 286.24
PRTA's Days Sales Outstanding is ranked lower than
93% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. PRTA: 286.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.41  Med: 30.97 Max: 115.61
Current: 286.24
12.41
115.61

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.56
PRTA's Price/Net Cash is ranked higher than
67% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. PRTA: 3.56 )
Ranked among companies with meaningful Price/Net Cash only.
PRTA' s Price/Net Cash Range Over the Past 10 Years
Min: 1.05  Med: 3.31 Max: 6.25
Current: 3.56
1.05
6.25
Price/Net Current Asset Value 3.50
PRTA's Price/Net Current Asset Value is ranked higher than
67% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 5.18 vs. PRTA: 3.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PRTA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.03  Med: 3.26 Max: 6.13
Current: 3.5
1.03
6.13
Price/Tangible Book 3.43
PRTA's Price/Tangible Book is ranked higher than
58% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PRTA: 3.43 )
Ranked among companies with meaningful Price/Tangible Book only.
PRTA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1  Med: 3.19 Max: 5.99
Current: 3.43
1
5.99
Price/Median PS Value 12.61
PRTA's Price/Median PS Value is ranked lower than
97% of the 679 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. PRTA: 12.61 )
Ranked among companies with meaningful Price/Median PS Value only.
PRTA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 0.85 Max: 13.76
Current: 12.61
0.1
13.76
Earnings Yield (Greenblatt) (%) -8.20
PRTA's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: -9.20 vs. PRTA: -8.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRTA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 111.4  Med: 142.90 Max: 74709.2
Current: -8.2
111.4
74709.2

More Statistics

Revenue (TTM) (Mil) $1.28
EPS (TTM) $ -2.89
Beta2.24
Short Percentage of Float20.16%
52-Week Range $28.20 - 76.42
Shares Outstanding (Mil)34.35

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 15 35 31
EPS ($) -3.61 -2.93 -2.06
EPS without NRI ($) -3.61 -2.93 -2.06
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Prothena (PRTA) Potential Parkinson's Treatment, Envivio (ENVI) Improved Results, Nike (NKE) Profita Mar 20 2015 
Three Stocks With Massive Insider Buying Sep 03 2014 

More From Other Websites
PROTHENA CORP PLC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to... May 25 2016
Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at... May 23 2016
Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at... May 23 2016
Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at... May 23 2016
Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st... May 19 2016
Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st... May 19 2016
Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st... May 19 2016
Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : May 17, 2016 May 17 2016
Coverage initiated on Prothena by Barclays May 13 2016
ETF’s with exposure to Prothena Corp. Plc : May 12, 2016 May 12 2016
PROTHENA CORP PLC Financials May 10 2016
Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an... May 09 2016
Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an... May 09 2016
Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an... May 09 2016
Prothena Corp. Plc :PRTA-US: Earnings Analysis: Q1, 2016 By the Numbers May 06 2016
Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : May 5, 2016 May 05 2016
Prothena (PRTA) Reports Wider-than-Expected Loss in Q1 May 04 2016
PROTHENA CORP PLC Files SEC form 10-Q, Quarterly Report May 04 2016
PROTHENA CORP PLC Files SEC form 8-K, Results of Operations and Financial Condition May 03 2016
Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update May 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)